Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Argus Health
Dow
US Army
Federal Trade Commission
Novartis
Queensland Health
Cantor Fitzgerald
Harvard Business School
Mallinckrodt

Generated: August 19, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 6,803,046 protect, and when does it expire?


Patent ► Subscribe protects KINEVAC and is included in one NDA.

This patent has ten patent family members in eight countries.

Summary for Patent: ► Subscribe

Title: Sincalide formulations
Abstract:The invention features sincalide formulations that include an effective amount of sincalide, a bulking agent/tonicity adjuster, a stabilizer, a surfactant, a chelator, and a buffer. The invention also features kits and methods for preparing improved sincalide formulations, as well as methods for treating, preventing, and diagnosing gall bladder-related disorders using sincalide formulations.
Inventor(s): Metcalfe; Edmund C. (Hillsborough, NJ), Monteferrante; Jo Anna (Raritan Township, NJ), Newborn; Margaret (Hamilton Township, NJ), Ropiak; Irene (Lawrenceville, NJ), Schramm; Ernst (North Brunswick, NJ), White; Gregory W. (Monmouth Junction, NJ), Zodda; Julius P. (Mercerville, NJ)
Assignee: Bracco International B.V. (Amsterdam, NL)
Application Number:10/222,540
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Use; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bracco
KINEVAC
sincalide
INJECTABLE;INJECTION017697-001Approved Prior to Jan 1, 1982RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China100374154► Subscribe
European Patent Office1631305► Subscribe
Germany60336509► Subscribe
Japan2006515321► Subscribe
Japan4751993► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
US Department of Justice
Novartis
Covington
Accenture
Julphar
Healthtrust
Medtronic
Harvard Business School
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot